Enable JavaScript to visit this website.


XELJANZ/​XELJANZ XR (tofacitinib) is a prescription medicine called a Janus kinase (JAK) inhibitor used to treat:

  • Adults with moderately to severely active ulcerative colitis when medicines called tumor necrosis factor (TNF) blockers did not work well or cannot be tolerated

It is not known if XELJANZ/​XELJANZ XR is safe and effective in children or in people with Hepatitis B or C.

XELJANZ/​XELJANZ XR is not recommended for people with severe liver problems.

XELJANZ/​XELJANZ XR may cause serious side effects, including Hepatitis B or C activation infection in people who carry the virus in their blood. If you are a carrier of the Hepatitis B or C virus (viruses that affect the liver), the virus may become active while you use XELJANZ/​XELJANZ XR. Your healthcare provider may do blood tests before you start treatment with XELJANZ/​XELJANZ XR and while you are using XELJANZ/​XELJANZ XR. Tell your healthcare provider if you have any of the following symptoms of a possible Hepatitis B or C infection: feel very tired, little or no appetite, clay-colored bowel movements, chills, muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach discomfort, or dark urine.

Common side effects of XELJANZ/​XELJANZ XR in ulcerative colitis patients include nasal congestion, sore throat, runny nose (nasopharyngitis), increased cholesterol levels, headache, upper respiratory tract infections (common cold, sinus infections), increased muscle enzyme levels, rash, diarrhea, and shingles (herpes zoster).

These are not all of the possible side effects of XELJANZ. Please see the Prescribing Information, including BOXED WARNING and Medication Guide, for additional information and complete details about XELJANZ.

Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit http://www.fda.gov/MedWatch or call 1-800-FDA-1088. By clicking on this link, you will be leaving UC.XELJANZ.com. This website is neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content and services of this site.